Development and Validation of a Stability‐Indicating HPLC‐UV Assay for Quantification of Tafenoquine Succinate in a Novel Paediatric Antimalarial Formulation
Biomedical Chromatography · 2026
DOI: 10.1002/bmc.70303 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2026. Verfasst von Madison L Bartlett und 5 weiteren Autor:innen. Beteiligte Einrichtung: Curtin Medical School, Curtin University, Bentley, Western Australia, Australia. Hauptthemen laut MEDLINE: Antimalarials, Aminoquinolines. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Tafenoquine, an 8‐aminoquinoline antimalarial, represents a promising advancement in combating malaria, but its bitter taste and lack of paediatric formulations hinder effective treatment for children. In response, we have formulated a chocolate‐based chewable tafenoquine tablet for paediatric use. A rapid, stability‐indicating high‐performance liquid chromatography method with ultraviolet detection was developed and validated for tafenoquine succinate quantification. Tablet samples were extracted with 85% methanol and analysed on a Waters XBridge C18 (150 × 4.6 mm, 5 μm) column using an isocratic mobile phase of 50 mM potassium dihydrogen orthophosphate buffer (pH 4.5) and acetonitrile (40:60, v/v). Detection was at 254 nm, with a retention time of 4.3 min. The method was linear over 0–313.6 μg/mL ( R 2 ≥ 0.999) with limits of detection and quantification of 2.22 and 6.73 μg/mL, respectively. Precision (RSD 0.15%–1.35%) and accuracy (101.48%–101.90%) met International Council for Harmonisation Q2 (R2) criteria. Forced degradation showed tafenoquine's susceptibility to acidic (29.33%), basic (18.83%), photolytic (complete degradation by day 14), and oxidative (8.33%) stress, with complete chromatographic separation from degradation products. This robust, rapid and low‐cost assay is suitable for routine content and stability testing, is adaptable to other tafenoquine formulations and can be further applied to clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Curtin Medical School, Curtin University, Bentley, Western Australia, Australia.
- Curtin Medical Research Institute, Curtin University, Bentley, Western Australia, Australia.
- Pharmacy, School of Allied Health, University of Western Australia, Perth, Western Australia, Australia.
- Institute for Paediatric Perioperative Excellence, The University of Western Australia, Perth, Western Australia, Australia.
- Wesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute, Nedlands, Western Australia, Australia.
ORCID-Profile: Madison L Bartlett
Zitieren
APA
Bartlett, M. L., Page-Sharp, M., Yoo, O., Nguyen, M. N., Lim, L. Y., & Moore, B. R. (2026). Development and Validation of a Stability‐Indicating HPLC‐UV Assay for Quantification of Tafenoquine Succinate in a Novel Paediatric Antimalarial Formulation. Biomedical Chromatography. https://doi.org/10.1002/bmc.70303
Vancouver
Bartlett ML, Page-Sharp M, Yoo O, Nguyen MN, Lim LY, Moore BR. Development and Validation of a Stability‐Indicating HPLC‐UV Assay for Quantification of Tafenoquine Succinate in a Novel Paediatric Antimalarial Formulation. Biomedical Chromatography. 2026. doi:10.1002/bmc.70303
BibTeX
@article{Bartlett2026,
author = {Bartlett, Madison L and Page-Sharp, Madhu and Yoo, Okhee and Nguyen, Minh N and Lim, Lee Yong and Moore, Brioni R},
title = {Development and Validation of a Stability‐Indicating HPLC‐UV Assay for Quantification of Tafenoquine Succinate in a Novel Paediatric Antimalarial Formulation},
journal = {Biomedical Chromatography},
year = {2026},
doi = {10.1002/bmc.70303}
}
EUVIMED